Navamedic ASA Reports Significant Growth in Q3 2025, Driven by Strategic Acquisitions Navamedic ASA has reported a robust 12.9% revenue increase in Q3 2025, reaching NOK 138.9 million, following a successful acquisition and expansion.

Navamedic ASA Reports Significant Growth in Q3 2025, Driven by Strategic Acquisitions #pharmaceuticals #Norway #Oslo #Addiction_Treatment #Navamedic_ASA

Navamedic ASA Reports Promising Growth Amid Challenges in 2025 Financials Navamedic ASA showcases solid revenue growth and strategic successes in its latest financial report for the first half of 2025, emphasizing resilience in its antibiotic portfolio.

Navamedic ASA Reports Promising Growth Amid Challenges in 2025 Financials #Norway #Oslo #Navamedic_ASA #Antibiotics_Portfolio #Flexilev_Product

Navamedic Secures Final Approvals for Flexilev® in All Nordic Countries Navamedic ASA proudly announces it has achieved final approvals necessary for the launch of Flexilev® in the Nordic nations. This marks a significant step towards personalized Parkinson's treatment.

Navamedic Secures Final Approvals for Flexilev® in All Nordic Countries #Norway #Oslo #Navamedic_ASA #OraFID #Flexilev

Navamedic ASA Completes Acquisition of dne pharma to Boost Addiction Treatment Services Navamedic ASA has successfully finalized the acquisition of dne pharma, marking a significant expansion into addiction treatment. The deal features key products like Ventizolve®.

Navamedic ASA Completes Acquisition of dne pharma to Boost Addiction Treatment Services #Norway #Oslo #Navamedic_ASA #dne_pharma #Ventizolve

Navamedic ASA Concludes Extraordinary General Meeting with Full Agenda Approval Navamedic ASA successfully held its Extraordinary General Meeting today, approving all agenda items as proposed by the board. Details inside.

Navamedic ASA Concludes Extraordinary General Meeting with Full Agenda Approval #Norway #Oslo #Navamedic_ASA #Extraordinary_General_Meeting #Kathrine_G._Andreassen

Navamedic ASA's Strategic Acquisition of dne pharma AS: A Game Changer for Healthcare Navamedic ASA has announced a significant acquisition of dne pharma AS, enhancing its market position in the healthcare sector with online presentations outlining the deal.

Navamedic ASA's Strategic Acquisition of dne pharma AS: A Game Changer for Healthcare #healthcare #Norway #Oslo #Navamedic_ASA #dne_pharma_AS

Navamedic ASA Releases Annual Report for 2024 with Key Insights Navamedic ASA has officially released its Annual Report for 2024, highlighting its commitment to public health and growth strategies in the Nordic region.

Navamedic ASA Releases Annual Report for 2024 with Key Insights #Oslo_Stock_Exchange #Norway #Annual_Report #Oslo #Navamedic_ASA

Navamedic ASA Expands Imdur® Distribution Agreement Until 2032 with TopRidge Pharma Limited Navamedic ASA has renewed its distribution agreement for Imdur® with TopRidge Pharma Limited, extending its reach until June 2032. This agreement highlights the importance of Imdur in Navamedic's portfolio.

Navamedic ASA Expands Imdur® Distribution Agreement Until 2032 with TopRidge Pharma Limited #Norway #Oslo #Navamedic_ASA #Imdur #TopRidge_Pharma

Navamedic Reports Promising Q4 2024 Results and Plans New Product Launches Navamedic ASA sees solid revenue growth and a vibrant pipeline in 2024 despite challenges, projecting continued expansion in the health sector.

Navamedic Reports Promising Q4 2024 Results and Plans New Product Launches #Norway #Oslo #Navamedic_ASA #Pharma_Growth #Eroxon_Launch